

Tong Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3818761/publications.pdf>

Version: 2024-02-01

39
papers

1,112
citations

471509

17
h-index

414414

32
g-index

41
all docs

41
docs citations

41
times ranked

1419
citing authors

#	ARTICLE	IF	CITATIONS
1	The enhancement role of Matrigel on HBV infection in HepG2-NTCP cells. <i>Journal of Virological Methods</i> , 2022, 299, 114345.	2.1	1
2	Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection. <i>Journal of Advanced Research</i> , 2022, 36, 201-210.	9.5	57
3	Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication. <i>IScience</i> , 2022, 25, 104136.	4.1	17
4	Hepatitis B Virus Pregenomic RNA Reflecting Viral Replication in Distal Non-tumor Tissues as a Determinant of the Stemness and Recurrence of Hepatocellular Carcinoma. <i>Frontiers in Microbiology</i> , 2022, 13, 830741.	3.5	1
5	A novel cell culture model reveals the viral interference during hepatitis B and C virus coinfection. <i>Antiviral Research</i> , 2021, 189, 105061.	4.1	10
6	The Genotype (A to H) Dependent N-terminal Sequence of HBV Large Surface Protein Affects Viral Replication, Secretion and Infectivity. <i>Frontiers in Microbiology</i> , 2021, 12, 687785.	3.5	9
7	The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 275.	17.1	40
8	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 415-423.	2.0	9
9	Nearly half of Ultrio plus NAT non-discriminated reactive blood donors were identified as occult HBV infection in South China. <i>BMC Infectious Diseases</i> , 2019, 19, 574.	2.9	15
10	The Effect of the Hepatitis B Virus Surface Protein Truncated sC69 ^Δ — Mutation on Viral Infectivity and the Host Innate Immune Response. <i>Frontiers in Microbiology</i> , 2019, 10, 1341.	3.5	3
11	The modulation of HBsAg level by sI126T is affected by additional amino acid substitutions in the S region of HBV. <i>Infection, Genetics and Evolution</i> , 2019, 75, 104006.	2.3	1
12	Hepatitis B Surface Antigen Activates Unfolded Protein Response in Forming Ground Glass Hepatocytes of Chronic Hepatitis B. <i>Viruses</i> , 2019, 11, 386.	3.3	35
13	Naturally Occurring Mutations within HBV Surface Promoter II Sequences Affect Transcription Activity, HBsAg and HBV DNA Levels in HBeAg-Positive Chronic Hepatitis B Patients. <i>Viruses</i> , 2019, 11, 78.	3.3	3
14	Novel HBV recombinants between genotypes B and C in 3 [′] -terminal reverse transcriptase (RT) sequences are associated with enhanced viral DNA load, higher RT point mutation rates and place of birth among Chinese patients. <i>Infection, Genetics and Evolution</i> , 2018, 57, 26-35.	2.3	9
15	Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1635-1644.	2.7	2
16	MADS-Box Transcription Factor MadsA Regulates Dimorphic Transition, Conidiation, and Germination of <i>Talaromyces marneffei</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 1781.	3.5	8
17	Characterization of Serum HBV RNA in Patients with Untreated HBeAg-Positive and -Negative Chronic Hepatitis B Infection. <i>Hepatitis Monthly</i> , 2018, 18, .	0.2	4
18	The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response. <i>Infection, Genetics and Evolution</i> , 2017, 49, 116-121.	2.3	1

#	ARTICLE	IF	CITATIONS
19	Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 909-915.	3.3	25
20	Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs. <i>Antiviral Therapy</i> , 2017, 23, 33-42.	1.0	5
21	Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2972-2982.	3.9	61
22	Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. <i>Journal of Hepatology</i> , 2017, 66, 288-296.	3.7	65
23	HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. <i>Viruses</i> , 2017, 9, 199.	3.3	2
24	Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2. <i>Infection, Genetics and Evolution</i> , 2016, 40, 275-281.	2.3	20
25	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. <i>Journal of Hepatology</i> , 2016, 65, 700-710.	3.7	331
26	On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. <i>World Journal of Hepatology</i> , 2016, 8, 1511.	2.0	7
27	Naturally occurring deletions/insertions in HBV core promoter tend to decrease in HBeAg-positive chronic hepatitis B patients during antiviral therapy. <i>Antiviral Therapy</i> , 2015, 20, 623-632.	1.0	14
28	Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 748-755.	2.8	26
29	Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. <i>Infection, Genetics and Evolution</i> , 2015, 33, 261-268.	2.3	16
30	Molecular characterization of resistance, virulence and clonality in vancomycin-resistant <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i> : A hospital-based study in Beijing, China. <i>Infection, Genetics and Evolution</i> , 2015, 33, 253-260.	2.3	52
31	Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naïve and lamivudine-treated patients with chronic hepatitis B. <i>Antiviral Research</i> , 2014, 102, 29-34.	4.1	18
32	Comparison of Abbott and Da-an real-time PCR for quantitating serum HBV DNA. <i>World Journal of Gastroenterology</i> , 2014, 20, 11762.	3.3	5
33	Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype. <i>Hepatology International</i> , 2013, 7, 443-450.	4.2	10
34	Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients. <i>Antiviral Research</i> , 2012, 96, 108-114.	4.1	17
35	Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. <i>Journal of Medical Virology</i> , 2012, 84, 207-216.	5.0	22
36	Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2010, 15, 1171-1178.	1.0	25

#	ARTICLE	IF	CITATIONS
37	Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. <i>Antiviral Research</i> , 2010, 85, 512-519.	4.1	83
38	Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection. <i>Liver International</i> , 2007, 27, 240-246.	3.9	26
39	Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2007, 42, 761-768.	5.1	50